Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief  in people with chronic dry eye: a review of the literature

Rhee, Michelle K.; Mah, Francis S.

doi:10.2147/opth.s113437

Cited by 18 publications

(9 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also a variety of corticosteroid-sparing antiinflammatory ophthalmic drops that have been shown to be effective and safe for long-term or even cyclical use in patients with dry eye and dry eye-related inflammation. Cyclosporine A 0.05% (Restasis; Allergan, Irvine, CA) is an ophthalmic drop that has been shown to be effective as a treatment for the signs of dry eye syndrome [42] and as an modulator of inflammatory markers on the ocular surface [43,44]. Cyclosporine A 0.05% works as an inhibitor of T cell proliferation and apoptosis of ocular surface cells [45].…”

Section: Discussionmentioning

confidence: 99%

Association of Ramadan daytime fasting with ocular surface inflammation and dry eye

et al. 2019

View full text Add to dashboard Cite

Purpose Despite the widespread practice of fasting, there are no studies looking at ocular surface inflammation, specifically matrix metalloproteinase 9 (MMP-9) testing, during fasting. In this prospective study, we wanted to evaluate the effect of Ramadan fasting on the level of tear film MMP-9 as well as other standard indicators of dry eye disease. Methods Forty healthy patients without history of ocular disease were tested before and toward the end of Ramadan. Each patient was assessed at each timepoint for tear film MMP-9 positivity as measured by a commercially available test (InflammaDry; Quidel Corp., San Diego, CA, USA) which detects MMP-9 levels of more than 40 ng/ml. Ocular surface disease index (OSDI) scores, tear breakup time (TBUT), Schirmer I test (S1T) and corneal fluorescein staining (CFS) were also evaluated at each timepoint. Results InflammaDry was positive in 10 patients (25%) prior to Ramadan and 21 patients (52.5%) during Ramadan fasting, and this change was statistically significant (p = 0.02). Mean TBUT decreased from 7 s prior to Ramadan to 5.3 s during Ramadan fasting, and this change was statistically significant (p = 0.01). OSDI, CFS and S1T did not show any statistically significant changes (p [ 0.05 for all). Conclusion Ramadan fasting has a significant impact on TBUT and ocular surface inflammation detected by Inflamma Dry testing. Patients who suffer from dry eye disease and those who develop symptoms during Ramadan are advised to consult with a physician before or during Ramadan fasting.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Ramadan daytime fasting with ocular surface inflammation and dry eye

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It has long played an important role in the field of the treatment of various immune-mediated disorders, such as psoariasis, and organ transplantation [129][130][131]. Topical cyclosporine A (tCSA) seems to be a promising treatment for DED since it is the first agent focused on the pathogenesis of this disease [132][133][134][135]. It works to restore the ocular surface, allowing increased production of tears by inhibiting the T-cell activation pathway [64,136].…”

Section: Cyclosporine Amentioning

confidence: 99%

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Kuo

Lin

Chien

et al. 2019

JCM

View full text Add to dashboard Cite

Dry eye disease (DED) has become common on a global scale in recent years. There is a wide prevalence of DED in different countries based on various ethnicities and environment. DED is a multifactorial ocular disorder. In addition to advanced age and gender, such factors as living at high altitude, smoking, pterygium, prolonged use of consumer electronics or overingesting of caffeine or multivitamins are considered to be the major risk factors of DED. We report the DED epidemiology in Taiwan firstly in this article. According to the pathophysiological factors and changes inthe composition of the tear film in DED, it can be categorized into several subtypes, including lipid anomaly dry eye, aqueous tear deficiency, allergic and toxic dry eye among others. Each subtype has its own cause and disease management; therefore, it is important for ophthalmologists to identify the type through literature review and investigation. The management of DED, relies not only on traditional medications such as artificial tears, gels and ointments, but also newer treatment options such as acupuncture, SYL1001, and nanomedicine therapy. We also conducted a comprehensive literature review including common subtypes and treatment of DED. Clearly, more clinical trials are needed to assess the efficacy and safety of the various treatments and common subtypes of DED.

show abstract

“…Inflammation is often a key driving mechanism in many cases of OSD, and therefore topical antinflammatory drugs (corticosteroids or non-steroidal antinflammatory drugs) are present in the market to treat this aspect of the pathology [3]. Cyclosporine can also be used to exploit its immune-modulating activity [4]. Antibiotics with antinflammatory action (such as azithromycin) may be used to treat Meibomian Gland Disease, often due to infective blepharitis [5].…”

Section: Current Treatments Of Dry Eyementioning

confidence: 99%

Age-Related Dry Eye Lactoferrin and Lactobionic Acid

Rusciano¹,

Pezzino²,

Olivieri³

et al. 2018

Ophthalmic Res

View full text Add to dashboard Cite

Dry eye is the most prominent pathology among those involving the ocular surface: a decrease of the aqueous (less frequent) or the lipid (more frequent) component of the tear film is the cause of the diminished stability of tears that is observed in this pathology. Dry eye shows a clear distribution linked to both sex (being more frequent among women) and age (increasing with aging). Therefore, specific treatments taking into account the etiology of the disease would be desired. The role of lactoferrin and its functional mimetic lactobionic acid are reported here as a possible remedy for age-related dry eye.

show abstract

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature

Cited by 18 publications

References 79 publications

Association of Ramadan daytime fasting with ocular surface inflammation and dry eye

Association of Ramadan daytime fasting with ocular surface inflammation and dry eye

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Age-Related Dry Eye Lactoferrin and Lactobionic Acid

Contact Info

Product

Resources

About